The three common signature characteristics of many neurological diseases are brain hypometabolism, oxidative stress, and neuroinflammation (Melo et al., 2011; Cai et al., 2012; Heneka et al., 2014). In order to be efficient, successful treatment should target all three pathologies simultaneously. Pyruvate seems to be an ideal candidate for such a treatment because of its unique combination of neuroprotective effects (Figure 1). In this opinion paper, we attempt to review and summarize recent information concerning these effects and their significance for neuroprotection.
No takes yet. Share an insight, caveat, or question.
Zilberter et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: